Over the past several years, glucagon-like peptide-1 (GLP-1) medications—such as Wegovy and Zepbound—have reshaped metabolic care. These drugs were originally developed for Type 2 diabetes, but now, when paired with diet and exercise, they are widely used for weight management, generating both curiosity and concern among employers and plan sponsors. In doing so, GLP-1s are creating complex financial decisions for employer-sponsored health plans.
With employee interest rising and clinical evidence expanding, many organizations are trying to determine whether offering GLP‑1 coverage is worth the substantial and growing cost. Employers will likely continue to make decisions on an annual basis about GLP-1 coverage and cost containment strategies.
This article analyzes the costs and benefits of health plan coverage of GLP-1s.
Growing demand for GLP-1 medications continues to be a top factor in rising health care costs in 2026. Surveys find that more employers are covering GLP-1s for weight loss, causing a significant impact on employer-sponsored health care spending.
A recent RAND report revealed that 12% of Americans have used GLP-1 medications for weight loss, and 14% are interested in using the drugs. According to KFF, more than 40% of people with employer-sponsored coverage meet clinical eligibility for GLP-1 medications. Despite this, fewer than 1 in 5 employers with over 200 employees currently cover GLP‑1s for weight loss purposes, even as employee interest continues to climb steadily.
This gap between eligibility and access is placing pressure on employers to consider whether providing GLP‑1 coverage is a necessary component of a competitive benefits package. At the same time, broader eligibility means broader financial exposure if coverage is granted without thoughtful guardrails.
GLP‑1s can help provide substantial health improvements. Users experience meaningful weight loss, better metabolic control and reduced cardiovascular risk, including lower rates of heart failure, stroke and obesity‑related complications. These benefits often translate into fewer inpatient hospitalizations and may contribute to long‑term improvements in workforce health.
Employers offering coverage report improved employee satisfaction and retention, particularly as obesity treatment becomes a more prominent priority for working‑age adults. In some industries, GLP‑1 coverage is increasingly viewed as a differentiator in the competition for talent, helping organizations both stand out to prospective employees and retain current talent.
The financial costs associated with GLP‑1 coverage stem largely from the medications’ high and persistent price point. GLP-1s are intended to be taken long term to fully achieve their benefits. This means that GLP-1 users may experience health benefits but will be required to use these high-cost treatments on an ongoing basis, placing GLP‑1s among the most expensive chronic medications employers cover on a recurring basis. These prices have immediate implications for pharmacy benefit budgets, especially as utilization accelerates.
The effect on health plan premiums is equally significant. According to the Employee Benefit Research Institute, simulation modeling indicates that expanding GLP‑1 coverage can raise employer health premiums by 6% to nearly 14% annually, depending on how widely the drugs are made available and how consistently members remain on therapy.
The most difficult aspect of the GLP‑1 cost-benefit equation is adherence. While consistent medication use improves outcomes, it also increases claims costs because of prolonged exposure to high monthly drug prices. It can be difficult to combine all of the factors, such as health risks, employee retention and culture, to get the full ROI picture.
Given that an employee is likely to remain on an employer’s plan for roughly four years—the average American worker tenure—the timeline for recouping costs through reduced medical utilization is often too short. This mismatch helps explain why GLP‑1 coverage remains financially challenging even as the clinical value becomes clearer. As with many benefits choices, the right choice can vary significantly by employer.
Many organizations are adopting more refined and targeted approaches, including the following, rather than offering unrestricted GLP‑1 coverage:
Using pre-tax dollars in an HRA can help cover a portion of the cost of GLP-1s. Employees submit claims and proof of payment for eligible expenses and then receive reimbursement from the HRA.
GLP‑1 medications can be a powerful tool for addressing Type 2 diabetes and obesity, offering impressive clinical benefits and the potential to support healthier, more productive employees. Yet these advantages come at a high price. For most employers, broad GLP‑1 coverage increases overall health care spending and raises premiums, but does provide some benefit to offset these costs. The most effective strategies may balance access with financial stewardship—focusing on targeted eligibility, strong utilization controls, integration with lifestyle programs and innovative plan designs.
As the GLP‑1 market evolves and potentially lower‑cost options emerge, employers who adopt measured, data‑driven approaches today will be best positioned to adapt their benefits strategy. Contact us for more information.
This website uses cookies. By accepting the use of cookies, this message will close and you will receive the optimal website experience. For more information on our cookie policy, please visit our Privacy Policy.
